Maxigesic® IV Phase 3 Exposure Study

NCT04005755 | Completed Phase 3 Results FDA Drug

• 1 other identifier: AFT-MXIV-11
• Study Type: interventional
• Target: 232
• Locations: 2 countries
• Sites: 4

Brief Summary

The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.

Conditions

Postoperative Pain

Keywords

Analgesic

Outcome Measures

Primary Outcomes (1)

• Incidence of TEAEs (Treatment-emergent Adverse Events)

  The incidence of treatment-emergent adverse events associated with exposure Maxigesic® IV

  During treatment period (≥ 48 hours - 5 days)

Secondary Outcomes (29)

• Time Course of TEAEs

  After receiving the first dose of study medication until 7 days after the last dose, a total of approximately 9 days for subjects who received the treatment for 48 hours and 12 days for subjects who received the treatment for 5 days.

• Incidence of TRAEs (Treatment-related Adverse Events)

  During treatment period (≥ 48 hours - 5 days)

• Incidence of TEAEs of Interest

  During treatment period (≥ 48 hours - 5 days)

• Changes in Blood Pressure

  From the baseline (Day 1 prior to surgery) until 7 days after the last dose

• Changes in Heart Rate

  From the baseline (Day 1 prior to surgery) until 7 days after the last dose

Study Arms (1)

Maxigesic® IV

EXPERIMENTAL

Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.

Drug: Maxigesic® IV

Interventions

Maxigesic® IV DRUG

acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion

Maxigesic® IV

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is male or female ≥ 18 years of age.
• Is classified by the anesthesiologist as P1 to P2 in the American Society of Anesthesiologists (ASA) Physical Status Classification System.
• Requires multiple doses of parenterally administered nonopioid analgesics over multiple days as a result of surgery (non-laparoscopic general, plastic or orthopedic surgery).
• Has an expected stay in facility ≥ 48 hours.
• Has a body weight ≥ 45 kg.
• If female and of childbearing potential, is nonlactating and nonpregnant.
• If female, is either not of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) or practicing 1 of the following medically acceptable methods of birth control: i) Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before study drug administration; ii) Total abstinence from sexual intercourse since the last menses before study drug administration through completion of final study visit; iii) Intrauterine device (IUD); iv) Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).
• Is able to provide written informed consent to participate in the study and able to understand the procedures and study requirements.
• Must voluntarily sign and date an informed consent form (ICF) that is approved by an Institutional Review Board (IRB) before the conduct of any study procedure.
• Is willing and able to remain at the study site for at least 48 hours and to attend a follow-up visit at 7 ± 2 days after the last dose of study drug.

You may not qualify if:

• Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or hypersensitivity, allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required on the day of surgery.
• Has experienced any surgical complications or other issues that, in the opinion of the Investigator, could compromise the safety of the subject if he or she participates in the study or could confound the results of the study.
• Has a known or suspected history of alcoholism or drug abuse or misuse within 2 years of screening or evidence of tolerance or physical dependence before dosing with study drug.
• Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the Investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
• Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the Investigator, would affect the subject's ability to comply with the study requirements.
• Has tested positive either on the urine drug screen or on the alcohol breathalyzer test. Subjects who test positive and can produce a prescription for the medication from their physician may be considered for study enrolment at the discretion of the Investigator.
• Has a history of a clinically significant (Investigator opinion) gastrointestinal (GI) event within 6 months before screening or has any history of peptic or gastric ulcers or GI bleeding.
• Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.
• Is considered by the Investigator, for any reason to be an unsuitable candidate to receive the study drug.
• Is receiving systemic chemotherapy, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).
• Is currently receiving anticoagulants (e.g. heparin or warfarin).
• Has received a course of systemic corticosteroids (either oral or parenteral) within 3 months before screening (inhaled nasal steroids and regional/limited area application of topical corticosteroids (Investigator discretion) are allowed).
• Has a history of chronic use (defined as daily use for \> 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional/limited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before screening and has not experienced any relevant medical problem.
• Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the upper limit of normal \[ULN\] for any liver function test, including aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], or creatinine ≥ 1.5 times the ULN).
• Has any clinically significant laboratory finding at screening that, in the opinion of the Investigator, contraindicates study participation.

Sponsors & Collaborators

• AFT Pharmaceuticals, Ltd.: lead

Study Sites (4)

Chesapeake Reserach Group

Pasadena, Maryland, 21122, United States

Location

Chapel Hill Research Group

Chapel Hill, North Carolina, 27514, United States

Location

Canterbury Geriatric Medical Research Trust

Christchurch, 8083, New Zealand

Location

Southern Clinical Trials

Christchurch, New Zealand

Location

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms

Results Point of Contact

• Title: Jennifer Zhang -Project Leader
• Organization: AFT Pharmaceuticals

jenniferz@aftpharm.com

+ 64 9 488 0232

Study Officials

• Ira Gottlieb, DPM

  Chesapeake Research Group

  PRINCIPAL INVESTIGATOR

• Simon Carson, MD

  Southern Clinical Trials Ltd

  PRINCIPAL INVESTIGATOR

• Gregory L Ruff, MD

  Chapel Hill Research Group

  PRINCIPAL INVESTIGATOR

• Nigel Gilchrist, MD

  CGM Research Trust

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 19, 2019
• First Posted: July 2, 2019
• Study Start: July 22, 2019
• Primary Completion: June 30, 2020
• Study Completion: July 7, 2020
• Last Updated: September 1, 2021
• Results First Posted: September 1, 2021

Record last verified: 2019-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (2); NZ (2)